spacer
home > ict > winter 2020 > the rise of direct-to-patient
PUBLICATIONS
International Clinical Trials

The Rise of Direct-to-Patient




The healthcare industry has changed its focus. The needs of the patient, rather than the needs of the industry, are now at the centre of clinical studies conducted. This patient-centric approach benefits the patient and, ultimately, the success and efficiency of clinical trials.

Conducting a trial can be complicated. With patients geographically spread out, in need of frequent doses, and a drug product that has strict storage and delivery conditions, the process is even more difficult. When dealing with homebound patients, an orphan indication, or a dispersed patient population, patient enrolment and retention can be a challenge.

Specialised clinical supply managers can help a sponsor execute a directto- patient programme to overcome fundamental challenges that prevent the sponsor from conducting a trial. The programme, which provides a highly customisable solution per patient and per protocol, helps reduce the number of patient dropouts and the overall cost of a study.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Brian Swites has over 30 years’ experience in the biopharmaceutical industry, specialising in global clinical supply chain management. As Senior Vice President of Clinical Services at Clinigen Group, Brian oversees global capabilities, strategic partnerships, and ensures overall growth and performance goals are being met. Prior to joining CSM, which later became part of Clinigen Group, Brian held various management positions during his 13 years at Cephalon/Teva Pharmaceuticals Industries. He received his Master’s Degree in Pharmaceutical Manufacturing from the Stevens Institute of Technology, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Brooks Introduces Azenta Life Sciences To Advance Innovative Sample Solutions

CHELMSFORD, Mass., Sept. 28, 2021 -- Today Brooks Automation, Inc. (Nasdaq: BRKS) announces Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta").
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement